Last reviewed · How we verify
Regular serum screening
At a glance
| Generic name | Regular serum screening |
|---|---|
| Also known as | Usual screening |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
- Effectiveness of Comprehensive Tertiary Interventions on Incidence and Clinical Outcomes of Birth Defects (NA)
- PUSH Plus Protein Pilot for Hip Fracture Patients (NA)
- Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals (PHASE4)
- Prevention of Postoperative Acute Kidney Injury (NA)
- T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regular serum screening CI brief — competitive landscape report
- Regular serum screening updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI